Acacia Pharma announces positive results from Phase IIa cancer cachexia study
The Phase IIa study was led by Professor Kenneth Fearon, Professor of Surgical Oncology and a world authority on cachexia, at the Royal Infirmary, Edinburgh, UK. Thirteen cancer patients, with an average weight loss of 11.4% (range 5-25%) in the previous six months, were treated with APD209 for up to eight weeks and detailed measurements of muscle size, muscle function, physical activity and quality of life were taken to assess the efficacy of the product.
Seven patients completed the eight week course of treatment, six achieving a major response, according to pre-defined criteria. These required an increase in quadriceps muscle size of at least 4% (measured by MRI) and/or an increase of at least 10% in quadriceps strength (measured with specialist strength and power equipment). Among the responders, the average increase in quadriceps volume was 6%, while quadriceps strength rose on average 16%. Hand grip strength increased on average 17%. Physical activity was markedly improved in three patients, the average daily step count more than doubling between the start and end of treatment in two of the patients. Although the population was frail and elderly, side effects considered to be related to APD209 were few and generally mild.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.